The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Presentations Seminar 1
1. Please click here to download the group picture of your seminar.
2. Presentations:
1. Therapeutic drug monitoring for all drugs and for all patients?
Dr Ute Blassmann, Heidelberg University Hospital, Germany
2. Do we need therapeutic drug monitoring for beta lactams or can we just use prolonged infusions?
Dr Ute Blassmann, Heidelberg University Hospital, Germany
3. The impact of PK/PD for clinical decisions
Dr Anouk Muller, HaaglandenMC, The Hague and ErasmusMC, Rotterdam
4. MIC directed therapy: why, when and what are the pitfalls?
Dr Anouk Muller, HaaglandenMC, The Hague and ErasmusMC, Rotterdam
5. Interactive Part – clinical cases – PK/PD
Prof Dr Isabel Spriet, UZ Leuven, Belgium
Dr Peter Declercq, University Hospitals Leuven, Belgium
6. Implementation of check of medication appropriateness: what can the computer do for ABS?
Prof Dr Isabel Spriet, UZ Leuven, Belgium
7. Antifungal therapy: what comes out of the pipeline in the near future?
Prof William Hope*, University of Liverpool, United Kingdom
8. TDM and PK/PD in antifungal therapy: when and why?
Prof William Hope*, University of Liverpool, United Kingdom
9. Antimicrobial prophylaxis in HSCT-patients: guidelines and evidence
Dr Philipp Wohlfarth, Medical University of Vienna, Austria
10. Hygiene measures, isolation and therapy
Prof Dr Annette Schuermans, University Hospitals Leuven, Belgium
11. What’s really new in antibiotic therapy
Prof Dr Martin J. Hug, Institute of Pharmaceutical Sciences, University of Freiburg, Germany
12. Interactive Part – PKPD & TDM of antifungals
Prof Dr Isabel Spriet, UZ Leuven, Belgium
Prof William Hope*, University of Liverpool, United Kingdom